NEW YORK, NY / ACCESSWIRE / October 29, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE:RFL). Investors who purchased Rafael shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rfl.
The investigation concerns whether Rafael and certain of its officers and/or directors have violated federal securities laws.
On October 28, 2021, Rafael issued a press release "announc[ing] that the AVENGER 500 Phase 3 clinical trial for CPI-613® (devimistat), Rafael Pharmaceuticals' lead product candidate, did not meet its primary endpoint of significant improvement in overall survival in patients with metastatic adenocarcinoma of the pancreas." On this news, Rafael's stock price fell sharply during intraday trading on October 28, 2021.
If you are aware of any facts relating to this investigation, or purchased Rafael shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/rfl. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC